ClinicalTrials.gg
RecruitingNCT06608823ARTISTUpdated Oct 29, 2026

ARTIST: Aortic Regurgitation Trial Investigating Surgery Versus Trilogy™

An interventional study of Transcatheter Aortic Valve Replacement (TAVR) using Trilogy THV System and SAVR in Aortic Regurgitation, Aortic Valve Insufficiency and Aortic Insufficiency, sponsored by JenaValve Technology, Inc.. Recruiting at 40 sites in United States. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by JenaValve Technology, Inc. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.
Updated Oct 29, 20266 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,016
Allocation
Randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 41 studies in Aortic Valve Insufficiency with a site in United States — 7 open to participants now, 17 under way, none of them phase 3. Aortic Valve Insufficiency · United States.

Planned enrollment
2nd of 24
1,016 · median 226
Started
2025
the only one that year
No phase
22 of 41
3 open now
Primary completion
2027-06
later than 7 of 16 live
Registered
38th of 41
by date
Lead sponsor
4 of 41
JenaValve Technology, Inc.

Among the 41 studies in Aortic Valve Insufficiency with a site in United States, this one is the 2nd largest by planned enrollment of the 24 interventional ones that give a count, is the only one that started in 2025, is one of 22 with no phase, reaches primary completion later than 7 of the 16 other live ones, and was the 38th registered.

Aortic Valve Insufficiency

171 studies on the registry are indexed under Aortic Valve Insufficiency; 56 are open to participants now.

Browse Aortic Valve Insufficiency studies →

Open to participants now

7 of the 41 studies in Aortic Valve Insufficiency with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 39 Aortic Valve Insufficiency studies recruiting now, 31 (79%) set no upper age limit and 2 (5%) stop at 75 or younger; 4 take children under 18; 4 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies in Aortic Valve Insufficiency with a site in United States, or all of them as a file.
02

Study summary

To demonstrate non-inferiority of the Trilogy Transcatheter Heart Valve (THV) System compared with surgical aortic valve replacement (SAVR) for treatment of subjects with clinically significant native aortic regurgitation (AR)

03

Conditions studied

  • Aortic Regurgitation
  • Aortic Valve Insufficiency
  • Aortic Insufficiency
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Clinical indication for AVR for native valve predominant AR defined as:

    1. Class I or II indication for AVR according to ACC/AHA or ESC/EACTS guidelines with moderate to severe or severe AR (Grade ≥3+) on transthoracic echocardiography, transesophageal echocardiography or cardiac MRI as assessed by the core laboratory OR
    2. AR severity that remains indeterminate despite core laboratory review of all imaging including at least one advanced imaging modality (TEE or cardiac MRI) AND evidence of left ventricular damage* from AR with unanimous agreement from the local heart team, an independent clinical evaluation committee and the CRB that the symptomatic subject ( II or greater) will benefit from SAVR for AR
  2. The subject is a candidate for TAVR using the Trilogy THV system and SAVR using a commercially approved bioprosthetic heart valve
  3. Subject and the treating physician agree that the subject will return for all required post-procedure follow-up visits
  4. Subject meets the legal minimum age to provide based on local regulatory requirements

Exclusion criteria

Exclusion Criteria:

  1. Confirmed moderate (2+) or less AR severity by core laboratory evaluation
  2. Estimated of less than 24 months due to associated non- cardiac comorbid conditions
  3. Subject is high-risk for SAVR as determined by the local heart team
  4. Subject refuses SAVR as a treatment option
  5. Subject refuses a blood transfusion
  6. Subject is selected for aortic valve repair or aortic surgery
  7. Marfan syndrome or other known connective tissue disease that would necessitate aortic root replacement/intervention
  8. Subject unable to undergo pre-procedure CT scan analysis for annular sizing
  9. Mitral or tricuspid disease, considered , such that if randomized to surgery, repair or replacement would be expected.
  10. Subject has a known or to all anticoagulation/antiplatelet medications (or inability to be anticoagulated for the index procedure), nitinol, or sensitivity to contrast media which cannot be adequately pre-medicated
  11. Hostile chest or conditions or complications from a prior surgery that would preclude safe reoperation (i.e., mediastinitis, radiation damage, chest wall abnormalities, adhesion of aorta or internal mammary artery (IMA) to the sternum)
  12. Need for emergency surgery or TAVR for any reason
  13. Cardiogenic shock manifested by low cardiac output, vasopressor dependence, or need for mechanical circulatory support
  14. Ongoing sepsis or active infective endocarditis with ongoing antibiotic (including suppressive) therapy or positive blood cultures within 6 weeks
  15. Cardiac resynchronization therapy (CRT) device implantation within 30 days of randomization
  16. \<25% according to core laboratory measurement of resting echocardiogram at time of screening
  17. Moderate to severe or worse right ventricular dysfunction on resting echocardiogram according to core laboratory
  18. Severe chronic liver disease ( C) or any active liver disease
  19. Chronic Kidney Disease Stage 4 or 5 (\<30 cc/min/1.73 m2 or dialysis)
  20. Severe Pulmonary Hypertension (pulmonary arterial systolic pressure

    • amp;amp;gt;2/3 systemic systolic pressure)
  21. Severe (COPD) with

    • amp;amp;lt;50% predicted or need for chronic supplementary oxygen
  22. Blood dyscrasia as defined: leukopenia (WBC \<3,000 Cells/μL), thrombocytopenia ( count \<50,000 Cells/μL), or anemia ( \<9.0 g/dL) that is uncorrected prior to randomization
  23. History of bleeding diathesis or coagulopathy that is not adequately treated
  24. Active gastrointestinal bleeding precluding anticoagulation or antiplatelet therapy
  25. Any condition considered a contraindication to mechanical circulatory support
  26. Uncontrolled atrial fibrillation (i.e., resting heart rate \>120 bpm)
  27. Evidence of an acute myocardial infarction ≤30 days before the index AVR
  28. Any percutaneous coronary or peripheral interventional procedure performed ≤30 days prior to AVR (Subjects with placement of coronary or peripheral stent(s) should be assessed for the ability to safely proceed with SAVR within the protocol timeframe)
  29. Symptomatic carotid or vertebral artery disease or successful treatment of carotid stenosis within six weeks of randomization
  30. Prior stroke with residual modified Rankin Score ≥2
  31. Stroke or (TIA) within 6 months of randomization
  32. (BMI) \<20 or \>50 kg/m2
  33. Currently participating in a cardiovascular drug or device trial and has not yet completed follow-up for the primary endpoint (excluding registries)
  34. Severe cognitive decline (resulting in either inability to provide for the trial/procedure, prevents independent lifestyle outside of a chronic care facility, or will fundamentally complicate rehabilitation from the procedure or compliance with follow-up visits)
  35. Other medical, social, or psychological conditions that in the opinion of the investigator preclude the subject from appropriate consent or adherence to the protocol required follow-up exams
  36. Pregnancy or intent to become pregnant prior to completion of all protocol follow-up requirements
  37. Anatomical exclusion criteria (ANY of the following):

    1. Congenital bicuspid, unicuspid or quadricuspid aortic valve verified by echocardiography or CCT core laboratory
    2. Native aortic annulus perimeter \<66 mm or \>90 mm per the core laboratory reading of baseline cardiac CT imaging
    3. Iliofemoral arteries with vessel characteristics unsuitable for sheath passage (e.g., calcification, tortuosity) as determined by the case review board (CRB)
    4. Significant abdominal or thoracic aortic disease (such as porcelain aorta, aneurysm, severe calcification, aortic coarctation) that would preclude safe passage of the delivery system or cannulation and aortotomy for SAVR
    5. According to the CRB, a combination of aortic root angulation (angle between the plane of the aortic valve annulus and horizontal plane/vertebrae), sinus size, and straight length of the aorta that will not allow safe device delivery and THV deployment
    6. Sinus of Valsalva anatomy that would prevent adequate coronary perfusion after valve implantation
  38. According to core laboratory evaluation, severe aortic stenosis
  39. Uncorrected hypertrophic obstructive cardiomyopathy
  40. Echocardiographic or Multi-slice CT (MSCT) evidence of untreated intracardiac mass or vegetation
  41. Left ventricular thrombus
  42. Left atrial thrombus without continuous appropriate anticoagulation within 90 days of the study procedure
  43. Complex coronary artery disease:

    1. Unprotected left main coronary artery disease ≥50%
    2. Syntax score \>32 (in the absence of prior revascularization)
    3. Heart Team determines that optimal revascularization cannot be adequately performed with EITHER CABG at the time of SAVR OR PCI at least 30 days prior to THV implant.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,016 participants (estimated)

Study arms

  • Experimental
    Transcatheter Aortic Valve Replacement (TAVR)

    Transcatheter Aortic Valve Replacement (TAVR) using the Trilogy THV System

    Device: Transcatheter Aortic Valve Replacement (TAVR) using Trilogy THV System

  • Other
    SAVR

    SAVR using commercially available surgical prosthetic valve

    Device: SAVR

Interventions

  • DeviceTranscatheter Aortic Valve Replacement (TAVR) using Trilogy THV System

    Transcatheter Aortic Valve Replacement (TAVR) with Trilogy Device

  • DeviceSAVR

    SAVR using commercially available surgical prosthetic valves.

06

What researchers measure

Primary outcomes

  1. All-Cause Mortality

    all-cause mortality at 12 months

    Time frame: 12 months

  2. All stroke

    Number of patients that had stroke

    Time frame: 12 months

  3. unplanned cardiac rehospitalization

    Number of patients who had unplanned cardiac rehospitalization

    Time frame: 12 months

Secondary outcomes

  1. Length of index hospitalization

    comparing TAVR length of index hospitalization with SAVR

    Time frame: pre-intervention/procedure surgery

  2. Echocardiographic effective orifice area

    comparing TAVR Echocardiographic effective orifice area with SAVR

    Time frame: 30 days

  3. Moderate or greater patient prosthesis mismatch as measured by echo

    comparing TAVR moderate or greater patient prosthesis mismatched with SAVR

    Time frame: 30 days or immediately after the intervention/procedure

  4. Kansas City Cardiomyopathy Questionnaire Overall Summary (KCCQ-OS)

    comparing change in KCCQ-OS in TAVR with SAVR. the minimum and maximum values vary based on the questionnaire. Higher scores mean better outcome.

    Time frame: 30 days

  5. Atrial fibrillation

    comparing the onset atrial fibrillation in TAVR with SAVR

    Time frame: 30 days

  6. Cardiovascular rehospitalization

    comparing the number of cardiovascular rehospitalizations in TAVR with SAVR

    Time frame: 30 days

  7. Composite primary endpoints

    comparing the superiority of the composite primary endpoint and its components in TAVR with SAVR

    Time frame: 30 days

  8. Composite primary endpoints

    comparing the superiority of the composite primary endpoint and its components in TAVR with SAVR

    Time frame: 1 year

  9. Major Adverse Cardiovascular and Cerebrovascular Events (MACCE)

    Freedom of Major Adverse Cardiovascular and Cerebrovascular Events

    Time frame: 30 days

  10. Major Adverse Cardiovascular and Cerebrovascular Events (MACCE)

    Freedom of Major Adverse Cardiovascular and Cerebrovascular Events

    Time frame: 6 months

  11. Major Adverse Cardiovascular and Cerebrovascular Events (MACCE)

    Freedom of Major Adverse Cardiovascular and Cerebrovascular Events

    Time frame: 1 year

  12. Major Adverse Cardiovascular and Cerebrovascular Events (MACCE)

    Freedom of Major Adverse Cardiovascular and Cerebrovascular Events

    Time frame: 2 years

  13. Major Adverse Cardiovascular and Cerebrovascular Events (MACCE)

    Freedom of Major Adverse Cardiovascular and Cerebrovascular Events

    Time frame: 3 years

  14. Major Adverse Cardiovascular and Cerebrovascular Events (MACCE)

    Freedom of Major Adverse Cardiovascular and Cerebrovascular Events

    Time frame: 4 years

  15. Major Adverse Cardiovascular and Cerebrovascular Events (MACCE)

    Freedom of Major Adverse Cardiovascular and Cerebrovascular Events

    Time frame: 5 years

  16. Major Adverse Cardiovascular and Cerebrovascular Events (MACCE)

    Freedom of Major Adverse Cardiovascular and Cerebrovascular Events

    Time frame: 6 years

  17. Major Adverse Cardiovascular and Cerebrovascular Events (MACCE)

    Freedom of Major Adverse Cardiovascular and Cerebrovascular Events

    Time frame: 7 years

  18. Major Adverse Cardiovascular and Cerebrovascular Events (MACCE)

    Freedom of Major Adverse Cardiovascular and Cerebrovascular Events

    Time frame: 8 years

  19. Major Adverse Cardiovascular and Cerebrovascular Events (MACCE)

    Freedom of Major Adverse Cardiovascular and Cerebrovascular Events

    Time frame: 9 years

  20. Major Adverse Cardiovascular and Cerebrovascular Events (MACCE)

    Freedom of Major Adverse Cardiovascular and Cerebrovascular Events

    Time frame: 10 years

07

Study locations

40 of 40 sites recruiting
08

References and documents

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Jun 2027, 24 months after the start.

Of 44 interventional studies with no phase under Aortic Valve Insufficiency, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 74. This study's planned 24 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 17, 2024
First posted
Sep 23, 2024
StartActual
Jun 18, 2025
Primary completionEst.
Jun 2027
CompletionEst.
Feb 2036
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
6 sites added
Show 6 added (6 United States)
  • Yale University · New Haven, United States
  • ProMedica Toledo Hospital · Toledo, United States
  • Providence St. Vincent Medical Center · Portland, United States
  • Swedish Medical Center · Seattle, United States
  • Northwestern University · Evanston, United States
  • NYU Langone · New York, United States
across 2 updates, Oct 26, 2026 – Oct 29, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Cedars-Sinai Medical Center · Los Angeles, United StatesContact m•••@cshs.org · •••9553→m•••@cshs.org · •••9553
Oct 26, 2026
Show all 2 updates
  1. Oct 29, 2026
    2 sites added
    Show 2 added (2 United States)
    • Northwestern University · Evanston, United States
    • NYU Langone · New York, United States
    + 1 other change: contact details
  2. Oct 26, 2026
    4 sites added
    Show 4 added (4 United States)
    • Yale University · New Haven, United States
    • ProMedica Toledo Hospital · Toledo, United States
    • Providence St. Vincent Medical Center · Portland, United States
    • Swedish Medical Center · Seattle, United States
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Cedars-Sinai Medical Center · Los Angeles, United StatesContact m•••@cshs.org · •••9553→m•••@cshs.org · •••9553

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06608823
Lead sponsor
JenaValve Technology, Inc.
Responsible party
Sponsor
First posted
Sep 23, 2024
Start date
Jun 18, 2025
Primary completion
Jun 2027 (estimated)
Completion
Feb 2036 (estimated)
Last update
Oct 29, 2026

Study contacts

Duane Pinto, MD MPH
Contact
pinto@jenavalve.com
949-767-2110
Vinod H Thourani, MD
principal investigator · Piedmont Heart Institute
Torsten P Vahl, MD
principal investigator · Columbia University
Raj Makkar, MD
principal investigator · Cedars-Sinai Medical Center
Hendrik Treede, MD
principal investigator · Department of Cardiovascular Surgery Johannes-Gutenberg University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion